|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.40 EUR | -0.68% |
|
+9.55% | +72.91% |
| 04/12 | Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug | MT |
| 04/12 | Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome | CI |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 419.1Cr | 456.4Cr | 517.1Cr | 590.7Cr | 619.1Cr | |||||
Short Term Investments | 131.1Cr | 67Cr | 3.2Cr | 76Cr | 7.5Cr | |||||
Trading Asset Securities, Total | 638.1Cr | 250.6Cr | 495Cr | 392.5Cr | 182.1Cr | |||||
Total Cash And Short Term Investments | 1.19TCr | 773.9Cr | 1.02TCr | 1.06TCr | 808.7Cr | |||||
Accounts Receivable, Total | 955.6Cr | 1.01TCr | 1.03TCr | 934.8Cr | 897.3Cr | |||||
Other Receivables | 258.7Cr | 292.8Cr | 313.3Cr | 317.4Cr | 321.5Cr | |||||
Notes Receivable | - | - | - | - | - | |||||
Total Receivables | 1.21TCr | 1.3TCr | 1.34TCr | 1.25TCr | 1.22TCr | |||||
Inventory | 1.1TCr | 1.13TCr | 1.36TCr | 1.39TCr | 1.35TCr | |||||
Other Current Assets, Total | 67Cr | 54Cr | 52Cr | 50Cr | 70Cr | |||||
Total Current Assets | 3.57TCr | 3.26TCr | 3.78TCr | 3.76TCr | 3.44TCr | |||||
Gross Property Plant And Equipment | 2.36TCr | 2.62TCr | 2.83TCr | 2.93TCr | 3.12TCr | |||||
Accumulated Depreciation | -1.19TCr | -1.35TCr | -1.47TCr | -1.59TCr | -1.78TCr | |||||
Net Property Plant And Equipment | 1.17TCr | 1.27TCr | 1.37TCr | 1.33TCr | 1.35TCr | |||||
Long-term Investments | 199.8Cr | 261.2Cr | 289.5Cr | 306Cr | 302.2Cr | |||||
Goodwill | 3.61TCr | 4.01TCr | 3.96TCr | 3.23TCr | 3TCr | |||||
Other Intangibles, Total | 2.16TCr | 2.2TCr | 2.04TCr | 1.98TCr | 1.84TCr | |||||
Accounts Receivable Long-Term | 10L | 2.4Cr | 2.4Cr | 2.3Cr | 2Cr | |||||
Loans Receivable Long-Term | - | - | - | - | - | |||||
Deferred Tax Assets Long-Term | 468.6Cr | 458Cr | 560.5Cr | 547.1Cr | 616.4Cr | |||||
Deferred Charges Long-Term | 441.8Cr | 431.2Cr | 379.7Cr | 355.8Cr | 371.8Cr | |||||
Other Long-Term Assets, Total | 85Cr | 138.3Cr | 105.5Cr | 114.9Cr | 158.1Cr | |||||
Total Assets | 12TCr | 12TCr | 12TCr | 12TCr | 11TCr | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 568.3Cr | 679.2Cr | 754.5Cr | 745.6Cr | 751.8Cr | |||||
Accrued Expenses, Total | 257.3Cr | 350.5Cr | 357.3Cr | 249.5Cr | 348.9Cr | |||||
Short-term Borrowings | - | - | - | - | - | |||||
Current Portion of Long-Term Debt | 835.8Cr | 415.5Cr | 757.9Cr | 653.6Cr | 500.4Cr | |||||
Current Portion of Leases | 21Cr | 24Cr | 28Cr | 29Cr | 31Cr | |||||
Current Income Taxes Payable | 226.9Cr | 69Cr | 105.6Cr | 62Cr | 55Cr | |||||
Unearned Revenue Current, Total | 362.8Cr | 409.1Cr | 419.8Cr | 391.1Cr | 368.4Cr | |||||
Other Current Liabilities | 1.4TCr | 993.8Cr | 1.09TCr | 814.6Cr | 840.1Cr | |||||
Total Current Liabilities | 3.67TCr | 2.94TCr | 3.51TCr | 2.95TCr | 2.9TCr | |||||
Long-Term Debt | 3.23TCr | 3.56TCr | 3.28TCr | 3.72TCr | 3.46TCr | |||||
Long-Term Leases | 92Cr | 93Cr | 95Cr | 94Cr | 94Cr | |||||
Unearned Revenue Non Current | 74Cr | 81Cr | 60Cr | 47Cr | 34Cr | |||||
Pension & Other Post Retirement Benefits | 845.4Cr | 717.5Cr | 438.8Cr | 401.4Cr | 331.2Cr | |||||
Deferred Tax Liability Non Current | 133.1Cr | 93Cr | 73Cr | 79Cr | 86Cr | |||||
Other Non Current Liabilities | 589.5Cr | 1.23TCr | 1.14TCr | 1.03TCr | 983.5Cr | |||||
Total Liabilities | 8.63TCr | 8.71TCr | 8.6TCr | 8.32TCr | 7.88TCr | |||||
Common Stock, Total | 251.5Cr | 251.5Cr | 251.5Cr | 251.5Cr | 251.5Cr | |||||
Retained Earnings | 1.31TCr | 1.33TCr | 1.72TCr | 1.22TCr | 986.7Cr | |||||
Comprehensive Income and Other | 1.5TCr | 1.72TCr | 1.9TCr | 1.82TCr | 1.95TCr | |||||
Total Common Equity | 3.05TCr | 3.3TCr | 3.88TCr | 3.29TCr | 3.19TCr | |||||
Minority Interest | 18Cr | 15Cr | 15Cr | 15Cr | 14Cr | |||||
Total Equity | 3.07TCr | 3.32TCr | 3.89TCr | 3.31TCr | 3.2TCr | |||||
Total Liabilities And Equity | 12TCr | 12TCr | 12TCr | 12TCr | 11TCr | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 98Cr | 98Cr | 98Cr | 98Cr | 98Cr | |||||
ECS Total Common Shares Outstanding | 98Cr | 98Cr | 98Cr | 98Cr | 98Cr | |||||
Book Value / Share | 31.07 | 33.61 | 39.47 | 33.52 | 32.48 | |||||
Tangible Book Value | -2.72TCr | -2.9TCr | -2.13TCr | -1.92TCr | -1.65TCr | |||||
Tangible Book Value Per Share | -27.68 | -29.56 | -21.67 | -19.54 | -16.83 | |||||
Total Debt | 4.18TCr | 4.09TCr | 4.17TCr | 4.5TCr | 4.08TCr | |||||
Net Debt | 2.99TCr | 3.31TCr | 3.15TCr | 3.44TCr | 3.27TCr | |||||
Debt Equivalent of Unfunded Proj. Benefit Obligation | 796.5Cr | 625.6Cr | 358.5Cr | 306.1Cr | 190.8Cr | |||||
Debt Equivalent Oper. Leases | 216.8Cr | 228.8Cr | 357.6Cr | 368.8Cr | 374.4Cr | |||||
Minority Interest, Total (Incl. Fin. Div) | 18Cr | 15Cr | 15Cr | 15Cr | 14Cr | |||||
Equity Method Investments, Total | 49Cr | 63Cr | 89Cr | 85Cr | 82Cr | |||||
Account Code - Inventory Valuation | 6 | 6 | 6 | 6 | 6 | |||||
Inventories - Raw Materials, Total | 265.2Cr | 201.1Cr | 269.5Cr | 251.5Cr | 208.1Cr | |||||
Inventories - Work In Process, Total | 821Cr | 916.4Cr | 1.07TCr | 1.13TCr | 1.12TCr | |||||
Inventories - Others | 9.9Cr | 14Cr | 22Cr | 14Cr | 15Cr | |||||
Land - (BS) | 907.1Cr | 982.7Cr | 1.05TCr | 1.07TCr | 1.16TCr | |||||
Machinery, Total | 1.2TCr | 1.32TCr | 1.46TCr | 1.53TCr | 1.66TCr | |||||
Full Time Employees | 95.96T | 95.95T | 97.92T | 96.93T | 91.86T | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | 62Cr | 65Cr | 70Cr | 64Cr | 58Cr |
- Stock Market
- Equities
- BAYN Stock
- Financials Bayer AG
- Balance Sheet
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















